Enterprise of Rosatom State Corporation
Print version

Industry news

Treatment Plans for Brain Metastases More Accurately Determined with Aid of Molecular Imaging Tracer

Imaging with the molecular imaging tracer 18F-FDOPA can help distinguish radiation-induced lesions from new tumor growth in patients who have been treated with radiation for brain metastases.

Ru-82 3D PET/CT MPI training leads to 94% inter-reader agreement

The Rubidium-ARMI (alternative radiopharmaceutical for myocardial imaging) multicenter trial has established a bar for assessing myocardial perfusion imaging (MPI).

NNSA Awards Funding to Accelerate Non-HEU-Based Production of Molybdenum-99 in the United States

The Department of Energy’s (DOE) National Nuclear Security Administration (NNSA) announced the award of a cooperative agreement that accelerates the dual objectives of eliminating the use of proliferation-sensitive highly enriched uranium (HEU) in the production of medical isotopes and establishing reliable domestic supplies of Molybdenum-99 (Mo-99) to meet U.S. patient needs.

NNSA, Rosatom, UK Ministry of Defence Hold Trilateral Nuclear Security Best Practices Workshop

Representatives from the U.S. National Nuclear Security Administration (NNSA), U.K.’s Ministry of Defence (MoD), and Russia’s State Atomic Energy Corporation “Rosatom” met Nov. 5-6 in Lisbon, Portugal, for the Eighth Nuclear Security Best Practices Exchange.

Research and Markets Estimates Global Market for Medical Imaging Devices at $30.2 billion

PET with 62Cu-ATSM, 62Cu-PTSM identifies hypoxia, perfusion in pulmonary lesions

Evaluating lung masses by visualizing hypoxia and perfusion is feasible with copper-diacetyl-bis (62Cu-ATSM) and copper-pyruvaldehyde-bis (62Cu-PTSM) PET scans.

Mallinckrodt Releases Letter Updating the Mo-99 Supply Outlook

Mallinckrodt released a customer letter which provides an update to the current outlook on Mo-99 availability for the remainder of 2013.

Gallium-68 DOTATOC Receives FDA Orphan Drug Designation for Neuroendocrine Tumor Management

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased to announce that the radiopharmaceutical Gallium-68 (DOTA0-Phel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the U.S.

Radioisotope ID’s high-risk, ruptured coronary plaques

PET-CT using the radioisotope 18F-sodium fluoride (18F-NaF) identified high-risk and ruptured plaques in patients with stable and unstable coronary heart disease.

PET/CT detects arterial plaques that cause heart attack

F-18 NaF PET/CT imaging may help identify patients at high risk of heart attack, according to a new study led by University of Edinburgh scientists.